Sign in to view content

High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis

Jared S. Nielsen, MD, MBA

Video
Published 2020

Related

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
Updates from the Field
2021
Fluctuations in Central Foveal Thickness and Vision Outcomes With AntiVEGF Therapy for Neovascular Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Updates from the Field
2020
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020

Category: Pharmacology

See more